We are live on ! Find out more
FP

Flagship Pioneering Portfolio holdings

AUM $1.16B
1-Year Est. Return 67.93%
This Fund
S&P 500
This Quarter Est. Return
+46.2%
1 Year Est. Return
+67.93%
3 Year Est. Return
-39.17%
5 Year Est. Return
-45.89%
10 Year Est. Return
–
AUM
$7.83B
AUM Growth
+$1.59B
Cap. Flow
-$6.23M
Cap. Flow %
-0.08%
Top 10 Hldgs %
99.18%
Holding
12
New
–
Increased
–
Reduced
1
Closed
–

Top Buys

No buys this quarter

Top Sells

Rank Stock Value
1
MCRB icon
Seres Therapeutics
MCRB
+$6.23M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MRNA icon
1
Moderna
MRNA
$21.5B
$4.84B 61.77%
20,581,016
– –
RUBY
2
DELISTED
Rubius Therapeutics, Inc
RUBY
$940M 12.01%
38,506,526
– –
SANA icon
3
Sana Biotechnology
SANA
$885M
$673M 8.6%
34,239,018
– –
MCRB icon
4
Seres Therapeutics
MCRB
$48.1M
$343M 4.38%
718,940
-14,759
-2% -$6.23M
EVLO
5
DELISTED
Evelo Biosciences, Inc. Common Stock
EVLO
$316M 4.04%
1,151,503
– –
DNLI icon
6
Denali Therapeutics
DNLI
$3.67B
$214M 2.74%
2,730,263
– –
KLDO
7
DELISTED
Kaleido Biosciences, Inc. Common Stock
KLDO
$146M 1.86%
19,575,710
– –
FHTX icon
8
Foghorn Therapeutics
FHTX
$285M
$135M 1.73%
12,674,120
– –
SGTX
9
DELISTED
Sigilon Therapeutics, Inc. Common Stock
SGTX
$111M 1.42%
797,721
– –
AXLA
10
DELISTED
Axcella Health Inc. Common Stock
AXLA
$50.3M 0.64%
501,937
– –
CDAK
11
DELISTED
Codiak BioSciences, Inc. Common Stock
CDAK
$48.3M 0.62%
2,607,303
– –
SYRS
12
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$16M 0.2%
293,849
– –

Similar funds

AC
AltraVue Capital Bellevue, Washington $1.16B AUM 46.45% 1-Year Est. Return
BI
Bramshill Investments Naples, Florida $1.16B AUM 0.86% 1-Year Est. Return
SCP
Sandhill Capital Partners Buffalo, New York $1.16B AUM 12.37% 1-Year Est. Return
SFG
SNS Financial Group Minneapolis, Minnesota $1.16B AUM 13.88% 1-Year Est. Return
GAB
German American Bancorp Jasper, Indiana $1.16B AUM 25.7% 1-Year Est. Return
AMI
Amica Mutual Insurance Providence, Rhode Island $1.16B AUM 21.34% 1-Year Est. Return
FFP
FourThought Financial Partners Venice, Florida $1.16B AUM 24.95% 1-Year Est. Return
MI
MMCAP International Grand Cayman, Cayman Islands $1.16B AUM 77.9% 1-Year Est. Return

Flagship Pioneering's Q2 2021 Portfolio in Review

As of Q2 2021, Flagship Pioneering held 12 positions worth $7.83B, up 25% from $6.24B the previous quarter. Its ten largest holdings account for 99% of the portfolio.

Trading was light in Q2 2021: portfolio turnover was 0%. Flagship Pioneering opened no new positions and made no exits, leaving the 12-position portfolio largely intact.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Flagship Pioneering's biggest Q2 2021 reduction was Seres Therapeutics, cutting an estimated $6.23M.
  • Flagship Pioneering's ten largest holdings make up 99% of its $7.83B portfolio in Q2 2021.
  • Flagship Pioneering opened 0 new positions and closed 0 in Q2 2021.
  • Flagship Pioneering's portfolio value rose 25% quarter-over-quarter to $7.83B.

Based on Flagship Pioneering's 13F filing for Q2 2021, filed 16 Aug 2021.